Dr Reddy's Labs gets 8 USFDA observations for Duwada facilities
Hyderabad: Drugmaker, Dr. Reddy's Laboratories has recently announced that the U. S. Food and Drug Administration (USFDA) has concluded an audit with 8 observations at its formulations manufacturing facilities (FTO 7 & FTO 9) at Duwada, Visakhapatnam.
"We have been issued a Form 483 with 8 (eight) observations, which we will address within the stipulated timeline," the company said in a BSE filing.
Medical Dialogues team had earlier reported that Dr. Reddy's Laboratories had received Form 483 with three observations from US health regulator after inspection at its manufacturing facility in Middleburg, New York.
Read also: Dr Reddy's Labs Gets USFDA 3 Observations For New York API Facility
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.